TriangleNCT03654833 · STUDY IN CONTEXT
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Draft scope assessment: unclear. Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
This will be assessed using CT scan evidence according to modified RECIST 1.1 criteria reporting. Scans will be undertaken every 6 weeks. Analysis will be timed from study entry using the baseline CT scan results until completion of treatment cycles, confirmed disease progression or death-whichever comes first. Complete response (CR): disappearance of all target and non-target lesions with no evidence of tumour elsewhere Partial response (PR): reduction of at least 30% in the sum of all measurements with no evidence of significant disease progression in non-target lesions or new lesions Progressive disease (PD): 1: increase of at least 20% in the sum of all measurements compared with the previous best response, 2: appearance of one or more significant (overall 20% increase in tumour diameters) new lesions, 3: significant increase in target lesions Stable disease (SD): neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD
This will be assessed using CT scan evidence according to modified RECIST 1.1 criteria reporting. Scans will be undertaken every 6 weeks. Analysis will be timed from study entry using the baseline CT scan results until completion of treatment cycles, confirmed disease progression or death - whichever comes first. Complete response (CR): disappearance of all target and non-target lesions with no evidence of tumour elsewhere Partial response (PR): reduction of at least 30% in the sum of all measurements with no evidence of significant disease progression in non-target lesions or new lesions Progressive disease (PD): 1: increase of at least 20% in the sum of all measurements compared with the previous best response, 2: appearance of one or more significant (overall 20% increase in tumour diameters) new lesions, 3: significant increase in target lesions Stable disease (SD): neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD
This will be assessed using CT scan evidence according to modified RECIST 1.1 criteria reporting. Scans will be undertaken every 6 weeks. Analysis will be timed from study entry using the baseline CT scan results until completion of treatment cycles, confirmed disease progression or death - whichever comes first. Complete response (CR): disappearance of all target and non-target lesions with no evidence of tumour elsewhere Partial response (PR): reduction of at least 30% in the sum of all measurements with no evidence of significant disease progression in non-target lesions or new lesions Progressive disease (PD): 1: increase of at least 20% in the sum of all measurements compared with the previous best response, 2: appearance of one or more significant (overall 20% increase in tumour diameters) new lesions, 3: significant increase in target lesions Stable disease (SD): neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- trial label
- Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
- applicability
- unclear
- applicability note
- Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 3
- harms Count
- 5
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0000
- source section id
- NCT03654833-om-0000
- source outcome index
- 0
- endpoint
- Disease Control Rate (DCR) at 12 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma.
- endpoint definition
- This will be assessed using CT scan evidence according to modified RECIST 1.1 criteria reporting. Scans will be undertaken every 6 weeks. Analysis will be timed from study entry using the baseline CT scan results until completion of treatment cycles, confirmed disease progression or death-whichever comes first. Complete response (CR): disappearance of all target and non-target lesions with no evidence of tumour elsewhere Partial response (PR): reduction of at least 30% in the sum of all measurements with no evidence of significant disease progression in non-target lesions or new lesions Progressive disease (PD): 1: increase of at least 20% in the sum of all measurements compared with the previous best response, 2: appearance of one or more significant (overall 20% increase in tumour diameters) new lesions, 3: significant increase in target lesions Stable disease (SD): neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD
- time origin
- 12 weeks
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0001
- source section id
- NCT03654833-om-0001
- source outcome index
- 1
- endpoint
- Disease Control Rate (DCR) at 24 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma.
- endpoint definition
- This will be assessed using CT scan evidence according to modified RECIST 1.1 criteria reporting. Scans will be undertaken every 6 weeks. Analysis will be timed from study entry using the baseline CT scan results until completion of treatment cycles, confirmed disease progression or death - whichever comes first. Complete response (CR): disappearance of all target and non-target lesions with no evidence of tumour elsewhere Partial response (PR): reduction of at least 30% in the sum of all measurements with no evidence of significant disease progression in non-target lesions or new lesions Progressive disease (PD): 1: increase of at least 20% in the sum of all measurements compared with the previous best response, 2: appearance of one or more significant (overall 20% increase in tumour diameters) new lesions, 3: significant increase in target lesions Stable disease (SD): neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD
- time origin
- 24 weeks
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0002
- source section id
- NCT03654833-om-0002
- source outcome index
- 2
- endpoint
- Objective Response Rate (ORR) at 24 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma.
- endpoint definition
- This will be assessed using CT scan evidence according to modified RECIST 1.1 criteria reporting. Scans will be undertaken every 6 weeks. Analysis will be timed from study entry using the baseline CT scan results until completion of treatment cycles, confirmed disease progression or death - whichever comes first. Complete response (CR): disappearance of all target and non-target lesions with no evidence of tumour elsewhere Partial response (PR): reduction of at least 30% in the sum of all measurements with no evidence of significant disease progression in non-target lesions or new lesions Progressive disease (PD): 1: increase of at least 20% in the sum of all measurements compared with the previous best response, 2: appearance of one or more significant (overall 20% increase in tumour diameters) new lesions, 3: significant increase in target lesions Stable disease (SD): neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD
- time origin
- 24 weeks
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0000
- arm key
- OG000
- arm label
- MiST-1
- regimen
- Rucaparib in DNA damage sensitive relapsed mesothelioma
- analyzed count
- 26
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03654833-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0000
- arm key
- OG001
- arm label
- MiST-2
- regimen
- Abemaciclib in p16INK4A negative mesothelioma
- analyzed count
- 26
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03654833-om-0000#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0000
- arm key
- OG002
- arm label
- MiST-3
- regimen
- Pembrolizumab and bemcentinib in relapsed mesothelioma
- analyzed count
- 26
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03654833-om-0000#groups/OG002
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0000
- arm key
- OG003
- arm label
- MiST-4
- regimen
- Atezolizumab and Bevacizumab in relapsed mesothelioma
- analyzed count
- 26
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03654833-om-0000#groups/OG003
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0000
- arm key
- OG004
- arm label
- MiST-5
- regimen
- Dostarlimab and Niraparib in Patients with Platinum Sensitive Relapsed Mesothelioma
- analyzed count
- 26
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03654833-om-0000#groups/OG004
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0001
- arm key
- OG000
- arm label
- MiST-1
- regimen
- Rucaparib in DNA damage sensitive relapsed mesothelioma
- analyzed count
- 26
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03654833-om-0001#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0001
- arm key
- OG001
- arm label
- MiST-2
- regimen
- Abemaciclib in p16INK4A negative mesothelioma
- analyzed count
- 26
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03654833-om-0001#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0001
- arm key
- OG002
- arm label
- MiST-3
- regimen
- Pembrolizumab and bemcentinib in relapsed mesothelioma
- analyzed count
- 26
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03654833-om-0001#groups/OG002
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0001
- arm key
- OG003
- arm label
- MiST-4
- regimen
- Atezolizumab and Bevacizumab in relapsed mesothelioma
- analyzed count
- 26
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03654833-om-0001#groups/OG003
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0001
- arm key
- OG004
- arm label
- MiST-5
- regimen
- Dostarlimab and Niraparib in Patients with Platinum Sensitive Relapsed Mesothelioma
- analyzed count
- 26
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03654833-om-0001#groups/OG004
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0002
- arm key
- OG000
- arm label
- MiST-1
- regimen
- Rucaparib in DNA damage sensitive relapsed mesothelioma
- analyzed count
- 26
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03654833-om-0002#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- outcome key
- om-0002
- arm key
- OG001
- arm label
- MiST-2
- regimen
- Abemaciclib in p16INK4A negative mesothelioma
- analyzed count
- 26
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT03654833-om-0002#groups/OG001
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- harm key
- EG000
- source section id
- NCT03654833-ae
- event group key
- EG000
- event group label
- MiST-1
- serious affected
- 9
- serious at risk
- 26
- other affected
- 24
- other at risk
- 26
- frequency threshold
- 5
- collection period
- From enrolment up to at least 6 months follow-up
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- harm key
- EG001
- source section id
- NCT03654833-ae
- event group key
- EG001
- event group label
- MiST-2
- serious affected
- 6
- serious at risk
- 26
- other affected
- 22
- other at risk
- 26
- frequency threshold
- 5
- collection period
- From enrolment up to at least 6 months follow-up
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- harm key
- EG002
- source section id
- NCT03654833-ae
- event group key
- EG002
- event group label
- MiST-3
- serious affected
- 10
- serious at risk
- 26
- other affected
- 24
- other at risk
- 26
- frequency threshold
- 5
- collection period
- From enrolment up to at least 6 months follow-up
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- harm key
- EG003
- source section id
- NCT03654833-ae
- event group key
- EG003
- event group label
- MiST-4
- serious affected
- 11
- serious at risk
- 26
- other affected
- 23
- other at risk
- 26
- frequency threshold
- 5
- collection period
- From enrolment up to at least 6 months follow-up
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-mesothelioma-recurrent-f0c1024d
- nct id
- NCT03654833
- harm key
- EG004
- source section id
- NCT03654833-ae
- event group key
- EG004
- event group label
- MiST-5
- serious affected
- 9
- serious at risk
- 26
- other affected
- 22
- other at risk
- 26
- frequency threshold
- 5
- collection period
- From enrolment up to at least 6 months follow-up
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice